acne vaccine

**Acne vaccine** is a non-specific umbrella term for experimental therapeutic vaccines being developed for **acne vulgaris**, rather than a single uniquely identified drug. Based on the provided context, it most prominently refers to **Sanofi's acne therapeutic vaccine program**, which originated from **Origimm's recombinant protein candidate ORI-001** and has been advanced by Sanofi as an **mRNA-based therapeutic vaccine** that entered **Phase I/II clinical testing in 2025**. These programs aim to induce an immune response against acne-associated **Cutibacterium acnes** antigens or virulence-associated factors while ideally sparing commensal strains and preserving the healthy skin microbiome. Other distinct experimental acne vaccines mentioned in the same context include a **peptide-based UC San Diego candidate** directed against the **HylA hyaluronidase A enzyme variant** from acne-associated C. acnes and a separate **recombinant protein vaccine** from **WestVac BioPharma**. Because the queried term refers to multiple different vaccine constructs and platforms, it should be treated as a non-specific drug/program label rather than one precisely defined product.

Other names

acne vaccine